Inherited ADAMTS13 mutations associated with Thrombotic Thrombocytopenic Purpura : a short review and update
ADAMTS13 is a plasma metalloprotease with the primary function of cleaving VWF to maintain hemostasis. Circulating ADAMTS13 is in the closed conformation until blood vessel injury triggers a VWF-dependant activation to the open active form of the protein. ADAMTS13 is a multi-domain protein with the domains broadly functioning to interact and cleave VWF or maintain global latency of ADAMTS13. Thrombotic Thrombocytopenic Purpura is a disease characterized by excessive thrombi formation in the microvasculature, diagnosis is made when ADAMTS13 activity is <10%. In the hereditary form, a variety of mutations are found throughout all domains of ADAMTS13, examples are given alongside details of each domain in this article. ADAMTS13 mutations can inhibit the binding and cleavage of VWF directly or indirectly through reduced secretion, leading to increased size of VWF multimers and platelet recruitment. Molecular characterization of ADAMTS13 may provide insight into the mechanisms of TTP to aid in both scientific and clinical research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Platelets - 34(2023), 1 vom: 08. Dez., Seite 2138306 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Markham-Lee, Zoe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADAM Proteins |
|---|
| Anmerkungen: |
Date Completed 09.11.2022 Date Revised 09.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09537104.2022.2138306 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347963501 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347963501 | ||
| 003 | DE-627 | ||
| 005 | 20231226035056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09537104.2022.2138306 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347963501 | ||
| 035 | |a (NLM)36281781 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Markham-Lee, Zoe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inherited ADAMTS13 mutations associated with Thrombotic Thrombocytopenic Purpura |b a short review and update |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2022 | ||
| 500 | |a Date Revised 09.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ADAMTS13 is a plasma metalloprotease with the primary function of cleaving VWF to maintain hemostasis. Circulating ADAMTS13 is in the closed conformation until blood vessel injury triggers a VWF-dependant activation to the open active form of the protein. ADAMTS13 is a multi-domain protein with the domains broadly functioning to interact and cleave VWF or maintain global latency of ADAMTS13. Thrombotic Thrombocytopenic Purpura is a disease characterized by excessive thrombi formation in the microvasculature, diagnosis is made when ADAMTS13 activity is <10%. In the hereditary form, a variety of mutations are found throughout all domains of ADAMTS13, examples are given alongside details of each domain in this article. ADAMTS13 mutations can inhibit the binding and cleavage of VWF directly or indirectly through reduced secretion, leading to increased size of VWF multimers and platelet recruitment. Molecular characterization of ADAMTS13 may provide insight into the mechanisms of TTP to aid in both scientific and clinical research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADAMTS13 | |
| 650 | 4 | |a Thrombotic Thrombocytopenic Purpura | |
| 650 | 4 | |a VWF | |
| 650 | 7 | |a von Willebrand Factor |2 NLM | |
| 650 | 7 | |a ADAM Proteins |2 NLM | |
| 650 | 7 | |a EC 3.4.24.- |2 NLM | |
| 650 | 7 | |a ADAMTS13 Protein |2 NLM | |
| 650 | 7 | |a EC 3.4.24.87 |2 NLM | |
| 650 | 7 | |a ADAMTS13 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.24.87 |2 NLM | |
| 700 | 1 | |a Morgan, Neil V |e verfasserin |4 aut | |
| 700 | 1 | |a Emsley, Jonas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Platelets |d 1990 |g 34(2023), 1 vom: 08. Dez., Seite 2138306 |w (DE-627)NLM091628660 |x 1369-1635 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:1 |g day:08 |g month:12 |g pages:2138306 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09537104.2022.2138306 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 1 |b 08 |c 12 |h 2138306 | ||